Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA sequencing of HepG2 cells treated with estradiol or estrogen receptor agonist

ABSTRACT: RNA sequencing of HepG2 cells treated with estradiol or estrogen receptor agonist

PROVIDER: PRJNA449680 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR6983690.fastq.gz	Fastqsanger.gz
	SRR6983691.fastq.gz	Fastqsanger.gz
	SRR6983692.fastq.gz	Fastqsanger.gz
	SRR6983685.fastq.gz	Fastqsanger.gz
	SRR6983686.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

RNA sequencing of HepG2 cells treated with estradiol or estrogen receptor agonist

Project description:We report differential expressed genes in HepG2 cells treated with control, E2, or an ER agonist

2018-12-10 | GSE112983 | GEO

Transcription profiling of rat peripheral blood leukocytes treated with the estrogen receptor agonists estradiol, PPT and DPN to investigates the functional roles of estrogen receptor alpha and beta

Project description:This experiment investigates the functional roles of estrogen receptor alpha and beta in peripheral blood leukocytes by using selective estrogen receptor agonists. The agonists that are used are estradiol (E2), the selective ER-alpha agonist PPT (4,4',4''-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol) and the selective ER-beta agonist DPN (2,3-bis(4-hydroxyphenyl)-propionitrile).

2007-05-30 | E-TABM-269 | biostudies-arrayexpress

Estradiol Treated Breast Cancer Cells Expressing Mutant Estrogen Receptors

Project description:MDA-MB-231 Breast Cancer Cells expressing either wild-type estrogen receptor or the mutant estrogen recepor L540Q were treated with estradiol for 1 or 2 hours Keywords: time-course

2004-03-24 | GSE1045 | GEO

Dynamics of protein expression reveals primary targets and secondary messengers of estrogen receptor signaling in MCF-7 breast cancer cells

Project description:Estrogen receptor-mediated proliferation of breast cancer cells is facilitated through expression of multiple primary target genes, products of which induce the secondary response to stimulation. To differentiate between the primary and secondary target genes of estrogen receptor signaling, we measured dynamics of protein expression induced by estradiol in MCF-7 breast cancer cells. Measurement of the global proteomic effects of estradiol by SILAC resulted in identification of 104 estradiol-regulated proteins, with only 41 corresponding genes having estrogen response elements (EREs). Selected reaction monitoring assays were used to validate 32 proteins and measure the dynamics of their expression within 72 hours upon estradiol stimulation and in the presence of 4-hydroxytamoxifen, thus confirming estrogen receptor-mediated signaling. Dynamics of protein expression revealed immediate early response proteins including TFF1 and CDK1 and delayed response proteins including CDK2 and NAB2. Presence or absence of EREs in the corresponding genes indicated early or delayed expression of proteins identified by SILAC. Finally, we measured accurate dynamics of estradiol-induced protein expression in the sub-network of primary and secondary targets of estrogen receptor. Interestingly, since NAB2 protein is also a repressor of EGR3-induced transcription, siRNA-mediated silencing of NAB2 resulted in the over-expression of some EGR3-induced proteins, such as ITGA2. To conclude, quantitative proteomics revealed secondary targets of estrogen receptor signaling potentially overlooked by genome-wide profiling of EREs and provided dynamics of protein expression in the network of transcription factors with a negative feedback loop.

2016-04-14 | PXD002797 | Pride

Estrogen receptor-depended gene signatures in the mouse mammary gland after acute estradiol treatment (RNA-Seq)

Project description:Estrogen receptor α (ERα) is the major driving transcription factor in normal mammary gland development as well as breast cancer initiation and progression.However,the fundamental mechanisms,including global cistromic and genomic transcriptional responses that are required to elicit mammary epithelial cell proliferation in response to estradiol, have not been elucidated. We used RNA-seq analysis to identify global gene expression signatures that are acutely regulated by estroegn receptors in the mouse mammary gland after acute estradiol treatment.

2019-07-23 | GSE130031 | GEO

Transcription profiling of human primary osteoblasts treated with estradiol or the pure antagonist ICI 182,780a potent inhibitor of estrogen receptor signaling

Project description:Transcriptional profiling of estrogen regulated genes in human primary osteoblasts. The cells were either treated with estradiol (1 nM) or the pure antagonist ICI 182,780 (Faslodex), which acts as a potent inhibitor of estrogen receptor signaling.

2007-08-01 | E-MEXP-1053 | biostudies-arrayexpress

Therapeutic Targeting of Ovarian Cancer Stem Cells Using Estrogen Receptor Beta Agonist

Project description:Therapeutic Targeting of Ovarian Cancer Stem Cells Using Estrogen Receptor Beta Agonist

| PRJNA809731 | ENA

Project description:Estrogen-related receptor γ agonist DY131 ameliorates lipopolysaccharide-induced acute liver injury

| PRJNA674766 | ENA

Transcription profiling of estradiol-treated human breast cancer cells expressing mutant estrogen receptors

Project description:MDA-MB-231 Breast Cancer Cells expressing either wild-type estrogen receptor or the mutant estrogen recepor L540Q were treated with estradiol for 1 or 2 hours

2007-07-19 | E-GEOD-1045 | biostudies-arrayexpress

Project description:DY131 is a pharmacological agonist of the orphan receptor estrogen-related receptor (ERR) γ which plays a crucial role in regulating energy generation, oxidative metabolism, cell apoptosis, inflammatory responses, etc. However, its role in acute liver injury is unknown. In the study, we evaluated the effect of DY131 on lipopolysaccharide (LPS)-induced liver injury. Transcriptomics analysis revealed that the dysregulated pathways associated with inflammation and metabolism were significantly reversed by DY131 in LPS-treated mice, providing more evidence in favor of the protective effect of DY131 against LPS-induced liver injury.

2020-11-06 | GSE160880 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data